<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIC-17012374</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-08-15</date_registration>
      <primary_sponsor>The Affiliated Hospital of Xuzhou Medical University</primary_sponsor>
      <public_title>Clinical study on the safety and efficacy of allogeneic hematopoietic stem cell transplantation combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies</public_title>
      <acronym />
      <scientific_title>Clinical study on the safety and efficacy of allogeneic hematopoietic stem cell transplantation combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-08-01</date_enrolment>
      <type_enrolment />
      <target_size>1:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=20069</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>B-cell hematologic malignancies</hc_freetext>
      <i_freetext>1:CAR-T cells;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jiang Cao</firstname>
        <middlename />
        <lastname />
        <address>99 Huaihai Road West, Xuzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13852432263</telephone>
        <email>zimu05067@163.com</email>
        <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Kailin Xu</firstname>
        <middlename />
        <lastname />
        <address>99 Huaihai Road West, Xuzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 0516 85802398</telephone>
        <email>lihmd@163.com</email>
        <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Aged 5-65 years;
2. Expected survival beyond 12 weeks;
3. Patients with B-cell hematologic malignancies, and consistent with allogeneic hematopoietic stem cell transplantation standards;
4. Creatinine &lt;2.5mg/dl;
5. ALT /AST&lt;3 normal value;
6. Bilirubin &lt; 2.0 mg/dl;
7. Karnofsky score &gt;50;
8. Patients without severe liver, kidney, heart disease;
9. Voluntary participation in the clinical trials.</inclusion_criteria>
      <agemin>5</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients in pregnancy or breast-feeding period; Planning pregnancy within 6 months;
2. HIV or active TB infected;
3. Active hepatitis B or hepatitis C infection;
4. Feasibility assessment during screening demonstrates &lt;10% transduction of target lymphocytes, or insufficient expansion (&lt;5-fold) in response to CD3/CD28 costimulation;
5. Patients with abnormal vital signs or could not cooperate with inspectors;
6. History of mental disorders;
7. Highly allergic constitution or severe allergies, especially allergic to IL-2;
8. Systemic infection or serious infections should be local anti-infection treatment;
9. With heart, lung, brain, kidney and other important organ dysfunction;
10. Presence of severe autoimmune disease;
11. Other situations we think improper for the research.  </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Complete remission rate;Progression Free Survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Overall Survival;Safety;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>1990-01-01</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>